<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Experimental and Clinical Surgery</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Experimental and Clinical Surgery</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник экспериментальной и клинической хирургии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2070-478X</issn><issn publication-format="electronic">2409-143X</issn><publisher><publisher-name xml:lang="en">Voronezh State Medical University named after N.N. Burdenko</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96</article-id><article-id pub-id-type="doi">10.18499/2070-478X-2014-7-2-152-158</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Treatment of Patients with Glaucoma in the Postoperative Period</article-title><trans-title-group xml:lang="ru"><trans-title>Лечение больных глаукомой в послеоперационном периоде</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Захарова</surname><given-names>И.А.</given-names></name><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Professor of Department of Ophthalmology Post-Graduate Education N.N. Burdenko Voronezh State Medical Academy</p></bio><bio xml:lang="ru"><p>д.м.н., проф. кафедры офтальмологии Института дополнительного профессионального образования Воронежской государственной медицинской академии им. Н.Н. Бурденко</p></bio><email>author@vestnik-surgery.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Авдеев</surname><given-names>Р.В.</given-names></name><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ph.D., Head of Department of Ophthalmology Post-Graduate Education N.N. Burdenko Voronezh State Medical Academy.</p></bio><bio xml:lang="ru"><p>к.м.н., зав. кафедрой офтальмологии Института дополнительного профессионального образования Воронежской государственной медицинской академии им. Н.Н. Бурденко</p></bio><email>author@vestnik-surgery.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Сурнин</surname><given-names>С.Н.</given-names></name><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>postgraduate student of Department of Ophthalmology Post-Graduate Education N.N. Burdenko Voronezh State Medical Academy.</p></bio><bio xml:lang="ru"><p>аспирант кафедры офтальмологии Института дополнительного профессионального образования Воронежской государственной медицинской академии им. Н.Н. Бурденко</p></bio><email>author@vestnik-surgery.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Burdenko Voronezh State Medical Academy, 10 Studencheskaia Str., Voronezh, 394036, Russian Federation</institution></aff><aff><institution xml:lang="ru">Воронежская государственная медицинская академия им. Н.Н. Бурденко, ул. Студенческая, д. 10, Воронеж, 394036, Российская Федерация</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-06-24" publication-format="electronic"><day>24</day><month>06</month><year>2014</year></pub-date><volume>7</volume><issue>2</issue><issue-title xml:lang="ru"/><fpage>152</fpage><lpage>158</lpage><history><date date-type="received" iso-8601-date="2016-04-26"><day>26</day><month>04</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-04-26"><day>26</day><month>04</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Voronezh N.N. Burdenko State Medical University</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Voronezh N.N. Burdenko State Medical University</copyright-holder><copyright-holder xml:lang="ru">ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnik-surgery.com/journal/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnik-surgery.com/journal/article/view/96">https://vestnik-surgery.com/journal/article/view/96</self-uri><abstract xml:lang="en"><p>The purpose of the study To study the effects of drugs affecting neurotransmitters - of neuromidin in patients undergoing antiglaucoma surgery. Material and methods 95 patients (190 eyes), operated on for uncompensated primary open angle glaucoma, divided into 2 groups. The first (main) group: 65 patients, which, together with the local hypotensive drugs and traditional therapy was received neiromidin 15 mg (1 ml) intramuscularly, and then in tablets of 20 mg x 2 times daily outpatient as monotherapy, 20 days. The second (control) group: 30 patients (60 eyes), who received similar treatment, but without the neuromidin. All of the patients were made classical surgery fistulizing with peripheral iridectomy modification S.N. Fedorov et al. The paper uses the standard ophthalmological research methods: visometry, tonometry, biomicroscopy, direct and inverse ophthalmoscopy, dynamic and static perimetry, gonioskopia and quantify disk on Heidelberg retina tomograph by laser scanning. The research was carried out before beginning treatment at hospital discharge and in process through 1, 3, 6, 9, 12 months. Results and their discussion Underwent surgical intervention resulted in lowering intraocular pressure in the main and control groups. In the group of patients treated with neuromidin, more marked significant improvement of visual functions, indicators HRT. Conclusion With the purpose of increase of efficiency of treatment of patients with primary glaucoma in the postoperative period it is recommended in complex treatment include neuromidin.The addition of neuromidin to traditional therapy improves visual acuity, the expansion of the field of view and increase the area of neironal rim, thickening peripapillary nerve fiber layer of the retina. Taking into account the decrease received positive effect six months after the operation, courses of drug therapy should be carried out 2 times in year.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования Изучить воздействие препарата, влияющего на нейромедиаторы – нейромидина, у пациентов, перенесших антиглаукомное оперативное вмешательство. Материал и методы 95 больных (190 глаз), оперированных по поводу некомпенсированной первичной открытоугольной глаукомы (ПОУГ), разделенные на 2 группы. Первая (основная) группа: 65 больных, которые, наряду с местными гипотензивными препаратами и традиционной терапией, получали нейромидин 15 мг (1мл) внутримышечно, а затем в таблетках по 20 мг х 2 раза в день в амбулаторных условиях в качестве монотерапии, 20 дней. Вторая (контрольная) группа: 30 больных (60 глаз), получавших аналогичное лечение, но без нейромидина. Всем больным была сделана классическая операция фистулизирующего типа – синустрабекулэктомия с периферической иридэктомией в модификации С.Н. Федорова с соавт. В работе использованы стандартные офтальмологические методы исследования: визометрия, тонометрия, биомикро- скопия, прямая и обратная офтальмоскопия, динамическая и статическая периметрия, гониоскопия, а также количественная оценка параметров диска на Гейдельбергском ретинальном томографе посредством лазерного сканирования. Исследования проводились до начала лечения, при выписке из стационара и в динамике через 1, 3, 6, 9,12 месяцев. Результаты и их обсуждение Проведенное хирургическое вмешательство приводило к снижению внутриглазного давления в основной и в контрольной группах. В группе пациентов, получавших нейромидин, отмечено более значительное улучшение зрительных функций, показателей HRT. Выводы С целью повышения эффективности лечения больных с первичной глаукомой в послеоперационном периоде рекомендуется в комплекс лечения включать нейромидин. Добавление нейромидина к традиционной терапии способствует повышению остроты зрения, расширению поля зрения и увеличению площади нейроретниального ободка, утолщению перипапиллярного слоя нервных волокон сетчатки. Учитывая снижение полученного положительного эффекта спустя 6 месяцев после операции, курсы медикаментозной терапии необходимо проводить 2 раза в год.</p></trans-abstract><kwd-group xml:lang="en"><kwd>glaucoma</kwd><kwd>postoperative period</kwd><kwd>neiromidin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>глаукома</kwd><kwd>послеоперационный период</kwd><kwd>нейромидин</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Alekseev V. N., O. Daub And Ate Hajj Put On Themselves, Nikitin D. N. Analiz osnovnyh prichin progressirovaniya pervichnoj glaukomy. Oftal'mologicheskie Vedomosti, [Analysis of the main reasons for the progression of primary glaucoma. Ophthalmological Vedomosti,] 2011; 4: 31-34.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Anisimov, S. Yu., Anisimov S. I., Calcina E. B. a Sovremennye podhody k nejroprotektornoj terapii glaukomy. Sovremennye tekhnologii lecheniya glaukomy. Materialy nauchno-prakticheskoj. [Modern approach to neuroprotective therapy of glaucoma. Modern technologies of treatment of glaucoma. The materials of scientific-practical.] Conf. "Fedorov readings". 2003; 192-198.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Gazizova I. R. Korrekciya mitohondrial'noj disfunkcii kak osnova nejroprotekcii pri glaukome. Oftal'mologicheskie Vedomosti, [the Correction of mitochondrial dysfunction as a basis for neuroprotection in glaucoma. Ophthalmological Vedomosti,] 2011: 4: 63-69.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Egorov E. A. Patogeneticheskie aspekty lecheniya pervichnoj glaukomy. Fiziologiya i patologiya vnutriglaznogo davleniya. [Pathogenetic aspects of treatment of primary glaucoma. Physiology and pathology of intraocular pressure.] Resp. SB. nauchn. works. 1983; 89-109.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Erichev V. P. Sovremennye principy gipotenzivnoj terapii glaukomy. Materialy nauchno-prakticheskoj. [Modern principles of hypotensive therapy of glaucoma. Materials of scientific and practical.] Conf. "Glaucoma: reality and perspectives". 2008; 220-222.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Kiseleva O. A., Robustova O. V., Immortal A. M., Zakharova E. K., Avdeev R. V. Rasprostranennost' pervichnoj glaukomy u predstavitelej raznyh ras i ehtnicheskih grupp v mire. Oftal'mologii, [Prevalence of primary glaucoma among representatives of different races and ethnic groups in the world. Ophthalmology,] 2013; 3: 5-8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Kiseleva O. A., Robustova O. V., Immortal A. M., Zakharova E. K., Avdeev R. V. Rasprostranennost' pervichnoj glaukomy u predstavitelej raznyh ras i ehtnicheskih grupp v Rossii i stranah SNG. Oftal'mologii, [Prevalence of primary glaucoma among representatives of different races and ethnic groups in Russia and the CIS. Ophthalmology,] 2013; 4: 11-15.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Kuryshev N. And. CHto delat', esli glaukoma progressiruet, nesmotrya na normal'noe VGD: amerikanskaya Akademiya oftal'mologii o diagnostike i lechenii glaukomy. Oftal'mologii, [What to do if glaucoma is progressing despite a normal IOP: American Academy of ophthalmology on diagnosis and treatment of glaucoma. Ophthalmology,] 2013: 1: 85-87.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Libman E. S. Invalidnost' vsledstvie narusheniya zreniya v Rossii. V Vserossijskij nacional'nyj forum. [Disability due to impaired vision in Russia. V Russian national forum.] SB. nauchn. works. 2012; 797-798.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Nesterov A. P. Patogenez i problemy patogeneticheskogo lecheniya pervichnoj glaukomy. Sovremennye tekhnologii lecheniya glaukomy. Pokazaniya Fedorova. Materialy nauchno-prakticheskoj. [Pathogenesis and problems of pathogenetic treatment of primary glaucoma. Modern technologies of treatment of glaucoma. Fedorov readings. The materials of scientific-practical.] Conf. 2003; 13-14.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Fedorov S. N., D. G. Ioffe, T. I. Ronkina Antiglaukomatoznye operacii - glubokaya sklerehktomiya. Vestnik oftal'mologii, [Antiglaucomatous surgery - deep sclerectomy. Vestnik of ophthalmology,] 1982; 4: 6-10.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Frolov M. A. Glaukoma kak mitohondrial'noj patologii. Klinicheskaya oftal'mologiya [Glaucoma as mitochondrial pathology. Clinical ophthalmology] 2011; 4: 122-123.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Bredesen D. E., Rao R. V., Mehlen P. Gibel' kletok v nervnoj sisteme. Priroda, [Cell death in the nervous system. Nature,] 2006;796-1264.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Iester M. Sloya nervnyh volokon setchatki, izmerennoj na Gejdel'bergskom tomografe setchatki i analizator nervnyh volokon [Retinal nerve fiber layer measured by Heidelberg retina tomograph and nerve fiber analyzer] M. Iester, A. Mermoud. Eur.J. Ophthalmol., 2005; 15: 246-254.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Cennamo G., Finelli M., Iaccarino G., de Crecchio G. [Tolshchina horioidei votkrytom-glaukoma izmereny spektral'no-domen skaniruyushchej lazernoj oftal'moskopii/opticheskaya kogerentnaya tomografiya. Oftal'molog, [Choroidal thickness inopen-angle glaucoma measured by spectral-domain scanning laser ophthalmoscopy/optical coherence tomography. Ophthalmologica,] 2012; 47-52.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Gloesmann M., B. Hermann, C. Schubert et al. Gistologicheskie korrelyacii svin'ya radial'nye rassloenie setchatki s ul'travysokojrazreshenie opticheskoj kogerentnoj tomografii [Histologic correlation of pig retina radial stratification with ultrahighresolution optical coherence tomography.] Invest. Ophthalmol. Vis. Sci., 2003; 96-103.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Hirooka K., Fujiwara A., Shiragami C et al. Vzaimosvyaz' mezhdu progressirovaniem povrezhdeniya zritel'nogo polya i tolshchina horioidei v glaza s normotenzivnaya glaukoma. [Relationship between progression of visual field damage and choroidal thickness in eyes with normal-tension glaucoma.] Clin. Exp. Ophthalmol., 2012; 576-582.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Krzystolik M. et al. Profilaktika ehksperimental'noj horioidal'noj neovaskulyarizacii s intravitreal'nym vvedeniem ingibitorov sosudistogo ehndotelial'nogo faktora rosta antitela fragment. [Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.] Arch. Ophthalmol., 2002; 120(3): 338-346.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Kuprjanowicz L., Karczewicz D. Nejroprotekciya pri glaukome. [Neuroprotection in glaucoma.] Ann. Acad. Med. Stetin., 2007; 53: 1: 22-29.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Latina M., Sibayan S., Dong H. Shin et al. Ophthalmology, 1998; 105: 11: 2082-2090.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Maul E. A., Friedman D. S., D. S. Chang et al. Tolshchina horioidei izmeryaetsya spektral'naya opticheskaya kogerentnaya tomografiya domen: faktory, vliyayushchie na tolshchinu u pacientov s glaukomoj. Oftal'mologii, [Choroidal thickness measured by spectral domain optical coherence tomography: factors affecting thickness in glaucoma patients. Ophthalmology,] 2011; 71-79.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Mwanza J. C., Hochberg, J. T., M. R. Banitt et al. Otsutstvie svyazi mezhdu glaukomoj i tolshchiny makulyarnoj horioidal'noj izmerena s bol'shej glubiny delaet opticheskoj kogerentnoj tomografii. [Lack of association between glaucoma and macular choroidal thickness measured with enhanced depthimaging optical coherence tomography.] Invest. Ophthalmol. Vis. Sci., 2011; 30-35.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Noecker, R. J., Kramer T. R., Latina M. Invest. Ophthalmol. Vis. Sci., 1998; 39: 472.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Rhew J. Y., Kim Y. T., Choi K. R. Izmerenie subfoveal'nyh tolshchina horioidei v normotenzivnaya glaukoma v korejskih pacientov. [Measurement of subfoveal choroidal thickness in normal-tension glaucoma in Korean patients.] J. Glaucoma, 2014; 1: 46-49.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Tatton W. G., Chalmers-Redman R. M., Tatton, N. A. Apoptoz i antiapoptoz v siqnal LinQ glaukome retinopatii. [Apoptosis and anti-apoptosis in siqnallinq qlaucomatous retinopathy.] Eur. J. Ophthalmology, 2001; 12-22</mixed-citation></ref></ref-list></back></article>
